Related Experiment Video

Updated: May 11, 2026

High Throughput Sequential ELISA for Validation of Biomarkers of Acute Graft-Versus-Host Disease
09:00

High Throughput Sequential ELISA for Validation of Biomarkers of Acute Graft-Versus-Host Disease

Published on: October 31, 2012

Comorbidity burden in patients with chronic GVHD

W A Wood1, X Chai, D Weisdorf

  • 1Lineberger Comprehensive Cancer Center, University of North Carolina at Chapel Hill, Chapel Hill, NC, USA.

Bone Marrow Transplantation
|May 14, 2013
PubMed

Insights

Comorbidity scoring, particularly the HCT-CI, helps predict survival in chronic graft-versus-host disease (cGVHD) patients. Higher scores indicate increased non-relapse mortality, especially with low platelet counts.

Area of Science:

  • Hematology
  • Transplant Immunology
  • Oncology

Background:

  • Chronic graft-versus-host disease (cGVHD) significantly impacts patient survival, quality of life, and functional status.
  • Understanding comorbidity burden is crucial for accurate prognostication and personalized treatment strategies in cGVHD.
  • Existing comorbidity indices require evaluation for their predictive performance in the context of cGVHD.

Purpose of the Study:

  • To assess the performance of the Functional Comorbidity Index (FCI) and Hematopoietic Cell Transplantation-specific Comorbidity Index (HCT-CI) in predicting outcomes for patients with cGVHD.
  • To determine the association between comorbidity scores at cGVHD diagnosis and non-relapse mortality (NRM) and overall mortality.
  • To investigate potential interactions between comorbidity scores and clinical factors, such as platelet count, in influencing mortality risk.

Main Methods:

  • A prospective cohort study was conducted with 239 patients diagnosed with cGVHD.
  • The FCI and HCT-CI were administered at the time of cGVHD cohort enrollment and compared to pre-hematopoietic cell transplant (HCT) assessments.
  • Statistical analyses, including hazard ratios (HR), were used to evaluate the association between comorbidity scores and mortality outcomes, considering interactions with platelet count.

Main Results:

  • Both FCI and HCT-CI identified a greater number of comorbidities at cGVHD enrollment compared to pre-HCT (P<0.001).
  • Higher HCT-CI scores at cGVHD enrollment were significantly associated with increased NRM (HR: 1.21; P=0.01).
  • An interaction between HCT-CI and platelet count was observed for overall mortality: higher HCT-CI predicted increased mortality risk when platelet count was ≤ 100,000/μL (HR: 2.01; P=0.01), but not when >100,000/μL (HR: 1.05; P=0.53).

Conclusions:

  • Comorbidity scoring, particularly the HCT-CI, is valuable for predicting survival outcomes in patients with cGVHD.
  • The HCT-CI demonstrates prognostic utility for both non-relapse mortality and overall mortality, with a notable interaction with platelet count.
  • Further research is warranted to explore other factors contributing to vulnerability in cGVHD patients beyond disease activity.

More Related Videos

Bone Marrow Transplantation Platform to Investigate the Role of Dendritic Cells in Graft-versus-Host Disease08:05

Bone Marrow Transplantation Platform to Investigate the Role of Dendritic Cells in Graft-versus-Host Disease

Published on: March 17, 2020

Related Concept Videos

Cytomegalovirus Disease01:27

Cytomegalovirus Disease

Cytomegalovirus (CMV) disease is caused by human cytomegalovirus, a double-stranded DNA virus of the Herpesviridae family. While primary CMV infection is often asymptomatic in immunocompetent individuals, the virus can cause severe disease in neonates and immunocompromised patients. CMV is the most common cause of congenital viral infection in the United States, and a major pathogen in solid organ and hematopoietic stem cell transplant recipients.CMV is transmitted via bodily fluids, sexual...
Chronic Obstructive Pulmonary Disease-III: Symptoms and Complications.01:25

Chronic Obstructive Pulmonary Disease-III: Symptoms and Complications.

Understanding the variety of primary symptoms and systemic complications that characterize chronic obstructive pulmonary disease (COPD) is crucial for healthcare professionals.
Symptoms of COPD can be classified as primary or systemic. Primary symptoms relate to reduced airflow, while systemic or extrapulmonary symptoms relate to COPD's broader impact on the body.
Primary Symptoms of COPD:
Chronic Kidney Disease II: Clinical Manifestations01:24

Chronic Kidney Disease II: Clinical Manifestations

Chronic Kidney Disease (CKD) progressively impairs multiple body systems due to the accumulation of uremic toxins, which disrupt cellular functions across various organs.Neurologic symptomsNeurologic symptoms often arise early in CKD, as uremic toxin buildup drives changes in cognitive and motor functions. Patients frequently experience fatigue, headache, confusion, difficulty concentrating, and, in severe cases, seizures. Peripheral neuropathy commonly manifests as burning sensations in the...
Graves Disease II: Pathophysiology01:24

Graves Disease II: Pathophysiology

Graves’ disease is an autoimmune disorder characterized by the production of thyroid-stimulating immunoglobulins (TSI) that activate TSH receptors, leading to excessive synthesis and release of thyroid hormones (T3 and T4) and resulting in hyperthyroidism.Among all causes of hyperthyroidism, Graves’ disease is the most common and can happen at any age, though it is more frequent in women. It produces a hypermetabolic state with features such as weight loss, tachycardia, tremor, and heat...
Chronic Obstructive Pulmonary Disease IV: Clinical Manifestations01:19

Chronic Obstructive Pulmonary Disease IV: Clinical Manifestations

Chronic Obstructive Pulmonary Disease, or COPD, is a long-term condition marked by persistent and only partially reversible airflow limitation. It involves two overlapping conditions—chronic bronchitis and emphysema—which often co-appear but differ in dominant symptoms and underlying mechanisms.Chronic Bronchitis FeaturesChronic bronchitis presents with a persistent productive cough and thick, sometimes purulent mucus due to airway inflammation, enlarged mucus glands, and goblet cell...
Heart Failure III: Clinical Manifestations01:26

Heart Failure III: Clinical Manifestations

Heart failure (HF) manifests primarily as dyspnea, fatigue, and fluid retention, resulting in peripheral and pulmonary edema. Symptoms may vary depending on which ventricle is more affected, left or right.Left-Sided Heart FailureAlso known as left ventricular failure, this condition results from the left ventricle's inability to fill or eject sufficient blood into the systemic circulation. It leads to pulmonary congestion, which occurs when the left ventricle fails to eject blood effectively...